Zhitong Financial App News, Kexing Pharmaceuticals (688136.SH) announced that its partner Zhejiang Haichang Biomedical Technology Co., Ltd. recently received the approval and issuance of a marketing license from the British Medicines and Health Products Administration to introduce the injectable paclitaxel (albumin binding) (Apexelsin®, hereinafter referred to as “albumin paclitaxel”) as a product. Indications for this drug: Treating various cancers such as metastatic breast cancer, metastatic pancreatic cancer, and non-small cell lung cancer.

Zhitongcaijing · 10/17 11:01
Zhitong Financial App News, Kexing Pharmaceuticals (688136.SH) announced that its partner Zhejiang Haichang Biomedical Technology Co., Ltd. recently received the approval and issuance of a marketing license from the British Medicines and Health Products Administration to introduce the injectable paclitaxel (albumin binding) (Apexelsin®, hereinafter referred to as “albumin paclitaxel”) as a product. Indications for this drug: Treating various cancers such as metastatic breast cancer, metastatic pancreatic cancer, and non-small cell lung cancer.